Table 2 Surgical and pathological outcomes of patients managed for hepatoblastoma
Characteristics | Number or as shown | Proportion (%) |
|---|---|---|
Liver resection | ||
 Hemihepatectomy (left hepatectomy + right hepatectomy) | 37 | 39.8 |
 Wedge resection | 17 | 18.3 |
 Trisectionectomy (left trisectionectomy + right trisectionectomy) | 13 | 14.0 |
 Bisegmentectomy (left lateral sectionectomy) | 9 | 9.7 |
 Central hepatectomy | 2 | 2.2 |
 Others | 15 | 16.1 |
Operative time [median (range)], minutes | 290 (100–510) | – |
Estimated blood loss [median (range)], ml/kg | 8.9 (1.7–111.1) | – |
Volume of red blood cells transfused [median (range)], ml/kg | 26.7 (0–111.1) | – |
Pathologic subtype | 93 | Â |
 Epithelial variants | 24 | 25.8 |
  Pure foetal variant with low mitotic activity | 3 | – |
  Foetal variant, mitotically active | 10 | – |
  Unspecified | 11 | – |
 Epithelial mixed | 11 | 11.8 |
 Mixed epithelial and mesenchymal | 41 | 44.1 |
  Without teratoid features | 2 | – |
  With teratoid features | 15 | – |
  Unspecified | 24 | – |
 Unknown | 17 | 18.3 |
Surgical margin | ||
 Positive | 7 | 7.5 |
 Negative | 69 | 74.2 |
 Unknown | 17 | 18.3 |
Microvascular involvement | ||
 Yes | 12 | 12.9 |
 No | 43 | 46.2 |
 Unknown | 38 | 40.9 |
Lymph node status (n = 31) | ||
 Positive | 0 | 0.0 |
 Negative | 31 | 100.0 |
Postoperative chemotherapy | ||
 Yes [n, median (range)] | 63, 6 (1–12) | 67.7 |
 No | 27 | 29.0 |
 Unknown | 3 | 3.2 |
Outcomes | ||
 Survived without relapse | 84 | 90.3 |
 Survived with relapse | 5 | 5.4 |
 Died from relapse | 4 | 4.3 |
Median follow-up duration [median (range)], months | 30.5 (0.7–105.1) | – |